Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Update

Vor Biopharma Inc. (NASDAQ:VOR) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 5,687,983 shares, a growth of 66.5% from the March 15th total of 3,416,161 shares. Approximately 11.7% of the shares of the stock are short sold. Based on an average daily volume of 1,387,708 shares, the short-interest ratio is currently 4.1 days.

Vor Biopharma Stock Down 0.6%

NASDAQ:VOR opened at $15.87 on Wednesday. The business’s 50-day moving average price is $14.53 and its two-hundred day moving average price is $16.69. Vor Biopharma has a twelve month low of $2.62 and a twelve month high of $65.80. The stock has a market cap of $775.25 million, a P/E ratio of -0.04 and a beta of 1.92.

Insider Transactions at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 135,201 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $16.59, for a total transaction of $2,242,984.59. Following the sale, the director owned 3,936,436 shares of the company’s stock, valued at approximately $65,305,473.24. This represents a 3.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 1,469,390 shares of company stock worth $24,749,633. Corporate insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $36,000. Goldman Sachs Group Inc. raised its holdings in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Vor Biopharma in the 2nd quarter valued at about $66,000. Chung Wu Investment Group LLC purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $109,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

Analyst Ratings Changes

VOR has been the topic of a number of recent research reports. TD Cowen initiated coverage on Vor Biopharma in a report on Wednesday, December 17th. They set a “buy” rating on the stock. Citigroup initiated coverage on Vor Biopharma in a report on Friday, January 9th. They set a “buy” rating and a $50.00 price objective on the stock. Wedbush increased their price objective on Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Jefferies Financial Group initiated coverage on Vor Biopharma in a report on Monday, March 30th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Wall Street Zen raised Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Saturday, April 4th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vor Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $50.67.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).